WhichPeps

Sobetirome

Small-molecule thyroid hormone receptor-beta agonist

Also known as: GC-1· development name
Dyslipidaemiametabolic and neurodege…
Generic peptide vial illustrationSobetirome
Evidence levelHuman evidence
Human evidencePhase I
Regulatory statusNo FDA/EMA approval identified

What you need to know in 20 seconds

What is it?Small-molecule thyroid hormone receptor-beta agonist
Research focusDyslipidaemia, metabolic and neurodegenerative research
Human evidencePeer-reviewed reviews describe historical Phase I oral exposure with short-term lipid target engagement, including substantial LDL-C reductions, but a fully retrievable primary clinical report remains limited and development did not yield an approved therapy.
Regulatory statusNo FDA/EMA-approved sobetirome medicine identified.
Main limitationsWeight-loss efficacy, long-term cardiovascular/disease outcomes, chronic safety or a current therapeutic regimen.
SafetyThyroid-axis effects and long-term hepatic/cardiovascular/bone safety require clinical definition.
i
Peer-reviewed reviews describe historical Phase I oral exposure with short-term lipid target engagement, including substantial LDL-C reductions, but a fully retrievable primary clinical report remains limited and development did not yield an approved therapy.

What the evidence actually supports

  • ✓Publish as early human pharmacology, not established obesity or lipid therapy.
  • ✓Do not present as a clinically proven weight-loss compound.
  • ✓Deep research coverage can be strong while clinical evidence remains Phase I.

What is not established / key limitations

  • ×No modern outcomes trial or approved indication followed.
  • ×No validated human weight-loss outcome established.
  • ×No validated long-term cardiovascular, weight-loss or disease-outcome benefit is established.

Selected study & evidence records

Sobetirome Phase I development summary

2008 · Phase I human development programme summarized in peer-reviewed review · n=24

Peer-reviewed development reviews report Phase I human exposure and LDL-lowering pharmacology, with the programme not progressing to an approved therapy.

Study detail → Primary source ↗

Historical sobetirome Phase I single- and multiple-dose study (reported in peer-reviewed reviews)

2008 · Randomized, double-blind, placebo-controlled early clinical study as reported in reviews · n=32 single-dose; 24 multiple-dose

Peer-reviewed reviews report LDL-C reductions up to 22% after single-dose exposure and up to 41% after the two-week multiple-dose phase.

Study detail → Primary source ↗

Safety and unknowns

Thyroid-axis effects and long-term hepatic/cardiovascular/bone safety require clinical definition.

Short Phase I exposure cannot establish long-term cardiovascular, skeletal, thyroid-axis or other thyromimetic safety.

Technical details

Mechanism / biologySelective thyroid hormone receptor-beta agonism designed to affect lipid metabolism with fewer TR-alpha-mediated cardiac effects.
Route / formulation boundaryThis is not a peptide and should not be grouped with peptide pharmacology.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusHistorical Phase I human dosing reported; primary trial publication not located. Historical development records report single rising oral doses and 14-day multiple-dose regimens in healthy men. Present only as Phase I exposure data with source limitations.
Identifiers & alternate namesGC-1 · GC1 · GC - 1 (SOBETIROME)

Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.